Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01961713|
Recruitment Status : Recruiting
First Posted : October 11, 2013
Last Update Posted : February 10, 2021
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy|
|Study Start Date :||April 2010|
|Estimated Primary Completion Date :||August 2022|
|Estimated Study Completion Date :||August 2022|
Subjects with prostate cancer diagnosed on prostate biopsy who undergo radical prostatectomy at Massachusetts General Hospital
- Relationship between CTC quantity and pathologic stage [ Time Frame: Up to 2 weeks after prostatectomy ]To evaluate the relationship between pre-operative CTC quantity and pathologic stage in men with early stage prostate cancer undergoing prostatectomy. Processing of the pathology specimen will require up to 2 weeks after surgery.
- Persistent CTC and biochemical recurrence [ Time Frame: 2 year ]To examine the relationship between persistent CTCs and biochemical recurrence after radical prostatectomy for localized prostate cancer
- Compare chromosome translocation status [ Time Frame: 2 years ]To compare the chromosome translocation status (TMPRSS2 fusion with ETS-related genes ERG, ETV1, ETV4, or ETV5) in CTCs with the primary tumor, and examine potential correlations between specific chromosomal translocations with biochemical recurrence.
- Explore other uses of CTCs captured [ Time Frame: 10 years ]To explore hypotheses about other uses of the CTCs captured with teh CTC-Chip, or the RNA or protein isolated from the CTCs, from the patients with localized prostate cancer for potential research and clinical applications.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01961713
|Contact: Richard J Lee, MD, PhD||617-724-4000|
|United States, Massachusetts|
|Massachsuetts General Hospital||Recruiting|
|Boston, Massachusetts, United States, 02114|
|Principal Investigator:||Richard J. Lee, MD, PhD||Massachusetts General Hospital|